Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

NCT01508910 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

291

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myocardial Ischemia
Refractory Angina Pectoris
Advanced Coronary Heart Disease

Interventions

BIOLOGICAL: Auto-CD34+ cells
BIOLOGICAL: Placebo: Diluent used to suspend Auto-CD34+ cells
OTHER: Standard of care

Sponsor

Lisata Therapeutics, Inc.